All blog posts
Total 255 results for
Showing 24 out of 255 results
03 September 2025
Herbert Smith Freehills Kramer comments for LSIPR on small molecule litigation in the UPC
31 July 2025
EU Regulatory Reform for Medicinal Products: Bolar exemption
30 July 2025
When will modifying a chemical scaffold be inventive? The UK Court of Appeal opines in the Xtandi case
21 July 2025
Trends emerging as the UPC enters its third year
19 May 2025
IP licensing: take care when considering market practices
13 May 2025
EU Regulatory Reform for Medicinal Products: Changes to MAs, supply, and transparency
30 April 2025
EU Regulatory Reform for Medicinal Products: Review of new regulatory exclusivities
25 February 2025
CJEU clears the way for single courts determining infringement actions in multiple jurisdictions without invalidity counterclaims interfering with the process (BSH Hausgerate v Electrolux)
11 February 2025
What's trending at the UPC? Is the UPC developing into a patentee friendly forum?
10 February 2025
Key Takeaways from the UPC Litigation Forum and Pharma & Biotech Patent Litigation Europe Summit 2025
29 January 2025
Could we…and would we..? UK CoA confirms that it is bound by previous precedent on second medical use SPCs
27 November 2024
UPC busy with main action decisions and key appeals so far in November 2024
Showing 24 out of 255 results
View moreKey contacts
Rebekah Gay
Partner, Head of Intellectual Property, Sydney
Laura Orlando
Managing Partner, Milan Office, Milan
Sue Gilchrist
Consultant, Sydney
Peng Lei
Partner, Herbert Smith Freehills Kramer Kewei Joint Operation, Mainland China and Shanghai
Alexandra Neri
Partner, Paris
Dr Ina vom Feld
Partner, Germany
Sebastian Moore
Partner, Head Intellectual Property, London and Milan
Rachel Montagnon
Knowledge Counsel, London